Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones sold 2,932 shares of the company’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the completion of the transaction, the chief financial officer directly owned 37,394 shares in the company, valued at approximately $1,013,003.46. The trade was a 7.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded down $0.04 during mid-day trading on Friday, reaching $27.18. 891,433 shares of the company were exchanged, compared to its average volume of 1,512,286. The business’s 50 day simple moving average is $32.20 and its 200 day simple moving average is $35.96. The company has a market capitalization of $1.58 billion, a P/E ratio of -3.88 and a beta of 0.89. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.93) by $0.15. The firm had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm’s quarterly revenue was up 43.3% on a year-over-year basis. During the same period in the prior year, the company posted $16.22 earnings per share. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Wall Street Analyst Weigh In

AGIO has been the subject of a number of research reports. Wall Street Zen downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Citigroup reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Friday, December 26th. Bank of America boosted their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. HC Wainwright upped their price target on Agios Pharmaceuticals from $48.00 to $62.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. Finally, Leerink Partners lifted their price objective on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $38.89.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of AGIO. CIBC Bancorp USA Inc. bought a new position in shares of Agios Pharmaceuticals during the third quarter worth about $242,000. CANADA LIFE ASSURANCE Co boosted its stake in Agios Pharmaceuticals by 3.4% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock valued at $796,000 after purchasing an additional 662 shares during the period. TCG Crossover Management LLC grew its position in Agios Pharmaceuticals by 105.2% in the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after purchasing an additional 733,038 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Agios Pharmaceuticals in the 3rd quarter worth about $5,881,000. Finally, Voleon Capital Management LP acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $268,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.